G. Borroni
Research Subjects
G. Borroni has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
F. Salerno
Dipartimento di Medicina Interna, Università degli Studi, IRCCS Policlinico S. Donato, San Donato Milanese, Milano, Italy
2 shared publicationsR. Ceriani
Unità Operativa di Medicina Generale ed Epatologia, Istituto Clinico Humanitas, Rozzano, Milan
2 shared publicationsB. Omazzi
Unità Operativa di Gastroenterologia, Azienda Ospedaliera G. Salvini, Rho
1 shared publicationC. Felline
Dipartimento di Patologia, Istituto Clinico Humanitas, Rozzano (MI), Italy
1 shared publicationC. Maltempo
Dipartimento di Patologia, Istituto Clinico Humanitas, Rozzano (MI), Italy
1 shared publicationM. A. Casiraghi
Unità Operativa di Medicina, Ospedale Civile di Legnano, Legnano
1 shared publication
Latest Publications
- 21 February 2008
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (9) , 790-797
Effectiveness of pegylated interferon/ribavirin combination in ‘real world’ patients with chronic hepatitis C virus infection
Clinical trials have shown that the combination of pegylated interferon/ribavirin induces a sustained virological response in 54-63% of patients with chronic hepatitis C virus infection, but its effectiveness in day-to-day clinical practice is less clear. To verify if the efficacy of pegylated interferon/ribavirin combination in 'real world' patients is comparable to that observed in trials. Methods The medical records of 397 consecutive naïve patients with chronic hepatitis C virus infection treated with pegylated interferon/ribavirin combination in nontertiary hospital settings were reviewed in order to assess the response to anti-viral treatment. The sustained virological response rate achieved in this population was similar to that recorded in registration trials (total population: 64%; genotype 1: 46%; genotypes 2-3: 84%). Also, the premature discontinuation rate (15%) was similar to that observed in registration trials, but there were fewer dose reductions in one or both medications (26%). We confirmed the association between adherence and sustained virological response among the patients infected with hepatitis C virus genotype 1 who were treated for > or =80% of the planned duration of treatment. The effectiveness of pegylated interferon/ribavirin therapy and factors predicting an sustained virological response in everyday clinical practice mirror those reported in randomized-controlled studies.
- 21 February 2008
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (9) , 790-797
Effectiveness of pegylated interferon/ribavirin combination in ‘real world’ patients with chronic hepatitis C virus infection
Clinical trials have shown that the combination of pegylated interferon/ribavirin induces a sustained virological response in 54-63% of patients with chronic hepatitis C virus infection, but its effectiveness in day-to-day clinical practice is less clear. To verify if the efficacy of pegylated interferon/ribavirin combination in 'real world' patients is comparable to that observed in trials. Methods The medical records of 397 consecutive naïve patients with chronic hepatitis C virus infection treated with pegylated interferon/ribavirin combination in nontertiary hospital settings were reviewed in order to assess the response to anti-viral treatment. The sustained virological response rate achieved in this population was similar to that recorded in registration trials (total population: 64%; genotype 1: 46%; genotypes 2-3: 84%). Also, the premature discontinuation rate (15%) was similar to that observed in registration trials, but there were fewer dose reductions in one or both medications (26%). We confirmed the association between adherence and sustained virological response among the patients infected with hepatitis C virus genotype 1 who were treated for > or =80% of the planned duration of treatment. The effectiveness of pegylated interferon/ribavirin therapy and factors predicting an sustained virological response in everyday clinical practice mirror those reported in randomized-controlled studies.
- 16 August 2006
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 24 (5) , 797-804
Comparison of simple tests for the non‐invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C
Summary: Background: Biopsy is the gold standard for assessing cirrhosis in patients with chronic hepatitis C virus infection, but it is expensive and at risk of complications. Alternative non‐invasive methods have been developed but their usefulness remains uncertain.Aim: To compare the accuracy of five non‐invasive scores in detecting cirrhosis.Methods: We reviewed the charts and liver biopsies of 228 consecutive, treatment‐naïve, hepatitis C virus‐positive patients, 13.2% of whom with histological diagnosis of cirrhosis. The five alternative scores were age‐platelet index, cirrhosis discriminant score, aspartate transaminases to platelet ratio index, Pohl's index, and aspartate transaminases/alanine transaminases ratio.Results: The specificities of the scores were good (87–100%), but not so their sensitivities (17–67%). Accordingly positive likelihood ratios were generally good but negative likelihood ratios were suboptimal. Combinations of the scores independently related to cirrhosis only slightly change this diagnostic accuracy. Using double cut‐offs to exclude/diagnoses cirrhosis, cirrhosis discriminant score classified 21% of patients without misdiagnoses and aspartate transaminases to platelet ratio index classified 85% of case with 9% of misdiagnoses.Conclusions: The five scores showed variable sensitivities and specificities in detecting liver cirrhosis, both individually and in combination. The use of double cut‐off points may make the cirrhosis discriminant score and aspartate transaminases to platelet ratio index useful to reduce the number of patients submitted to liver biopsy.
- 16 August 2006
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 24 (5) , 797-804
Comparison of simple tests for the non‐invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C
Summary: Background: Biopsy is the gold standard for assessing cirrhosis in patients with chronic hepatitis C virus infection, but it is expensive and at risk of complications. Alternative non‐invasive methods have been developed but their usefulness remains uncertain.Aim: To compare the accuracy of five non‐invasive scores in detecting cirrhosis.Methods: We reviewed the charts and liver biopsies of 228 consecutive, treatment‐naïve, hepatitis C virus‐positive patients, 13.2% of whom with histological diagnosis of cirrhosis. The five alternative scores were age‐platelet index, cirrhosis discriminant score, aspartate transaminases to platelet ratio index, Pohl's index, and aspartate transaminases/alanine transaminases ratio.Results: The specificities of the scores were good (87–100%), but not so their sensitivities (17–67%). Accordingly positive likelihood ratios were generally good but negative likelihood ratios were suboptimal. Combinations of the scores independently related to cirrhosis only slightly change this diagnostic accuracy. Using double cut‐offs to exclude/diagnoses cirrhosis, cirrhosis discriminant score classified 21% of patients without misdiagnoses and aspartate transaminases to platelet ratio index classified 85% of case with 9% of misdiagnoses.Conclusions: The five scores showed variable sensitivities and specificities in detecting liver cirrhosis, both individually and in combination. The use of double cut‐off points may make the cirrhosis discriminant score and aspartate transaminases to platelet ratio index useful to reduce the number of patients submitted to liver biopsy.